Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.48 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 7/20 | 0.34 |
| ▸ | NOS2 | P35228 | 7/20 | 0.34 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 3/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6242823 | 0.98 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL7065377 | 0.98 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL11796568 | 0.98 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL6245099 | 0.98 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL2692193 | 0.96 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL4424531 | 0.94 | TRIM24 (0.46) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL2692046 | 0.93 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL2693759 | 0.88 | TRIM24 (0.39) | TRIM24TRIM33ALDH1A1HTTNOS1 | |
| SCHEMBL2690522 | 0.86 | TRIM24 (0.38) | TRIM24TRIM33ALDH1A1CA1CA2 | |
| SCHEMBL2691711 | 0.85 | TRIM24 (0.40) | TRIM24TRIM33ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491745-B2 | Pyrrole-Type compounds, compositions and methods for treating cancer or viral disease | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2007-02-15 | — | — | US | disclosed |
| EP-1431286-A2 | Prodigiosin derivatives for treating cancer or viral diseases | Gemin X Biotechnologies Inc. (CA) | 2004-06-23 | — | — | EP | disclosed |
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X BIOTECHNOLOGIES INC. | 2004-01-22 | — | — | US | disclosed |
| US-6602879-B2 | For inhibiting the replication or infectivity of a virus; therapy | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2003-08-05 | — | — | US | disclosed |
| US-20030009032-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2003-01-09 | — | — | US | disclosed |
| EP-1255753-A2 | PRODIGIOSIN-DERIVATIVES AS NEOPLASTIC AND ANTI-VIRAL AGENTS | Gemin X Biotechnologies Inc. (CA) | 2002-11-13 | — | — | EP | disclosed |
| US-6407244-B1 | ANTIPROLIFERATIVE AGENT | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2002-06-18 | — | — | US | disclosed |
| WO-2001055131-A2 | PRODIGIOSIN-DERIVATIVES AS NEOPLASTIC AND ANTI-VIRAL AGENTS | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | POLI, PYCR1, ZC3HAV1 | TRIM24 1078/4885TRIM33 841/4885ALDH1A1 3326/4885 |
| US-20030009032-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | POLI, PYCR1, ZC3HAV1 | TRIM24 1078/4885TRIM33 841/4885ALDH1A1 3326/4885 |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | POLI, PCNA, ELL | TRIM24 722/4885TRIM33 1839/4885ALDH1A1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.